Presepsin在儿童脓毒症中的研究进展

doi:10.12372/jcp.2023.22e1144

摘要/Abstract

摘要：

脓毒症是一种危及生命的疾病，是造成儿科患者发病、乃至死亡的主要原因之一，早期诊断并及时治疗可提高患儿生存率。血培养、C-反应蛋白（CRP）、降钙素原（PCT）、白细胞介素-6（IL-6）等在脓毒症诊断中的应用是目前研究的热点，但其特异度和灵敏度都有局限性，且检测时间过长。可溶性白细胞分化抗原14亚型（sCD14-ST）又称Presepsin，是一种新型生物标志物，它不仅对儿童脓毒症的早期诊断有较高的特异度和灵敏度，对判定脓毒症病情严重程度、抗菌药物治疗效果和预后也有一定的评估价值，且检测方法快捷、准确，具有临床应用的可行性。文章就Presepsin对脓毒症诊断价值评价的研究进行综述，以期开展更多的临床研究指导其应用。

关键词: 可溶性白细胞分化抗原14亚型, 脓毒症, 儿童

Abstract:

Sepsis, a life-threatening disease, is one of the main causes of morbidity and even death in pediatric patients. Early diagnosis and timely treatment can improve the patient survival rate. The application of blood culture, C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6) in the diagnosis of sepsis is a hot spot of current research, but its specificity and sensitivity are limited, and the detection time is too long. Soluble leukocyte differentiation antigen 14 subtype (sCD14-ST, or Presepsin) is a novel biomarker that not only has high specificity and sensitivity in the early diagnosis of sepsis in children, but also has certain value in evaluating the severity of sepsis, antimicrobial treatment and prognosis, and the detection method is fast and accurate. It has the feasibility of clinical application.This article reviews the evaluation of Presepsin in the diagnosis of sepsis, with a view to conducting more clinical studies to guide its application.

Key words: soluble leukocyte differentiation antigen 14 subtype, sepsis, child

刘静, 杨新利, 史宝海, 张清秀. Presepsin在儿童脓毒症中的研究进展[J]. 临床儿科杂志, 2023, 41(11): 870-874.

LIU Jing, YANG Xinli, SHI Baohai, ZHANG Qingxiu. Research Progress of Presepsin in Children with Sepsis[J]. Journal of Clinical Pediatrics, 2023, 41(11): 870-874.

参考文献 40

[1]	程晔, 应佳云, 刘彦婷, 等. 《2020拯救脓毒症运动国际指南:儿童脓毒性休克和脓毒症相关器官功能障碍管理》解读[J]. 中国小儿急救医学, 2020, 27(4): 241-248.
[2]	Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children[J]. Pediatr Crit Care Med, 2020, 21(2): e52-e106. doi: 10.1097/PCC.0000000000002198
[3]	Balamuth F, Weiss SL, Neuman MI, et al. Pediatric severe sepsis in U.S. children's hospitals[J]. Pediatr Crit Care Med, 2014, 15(9): 798-805. doi: 10.1097/PCC.0000000000000225
[4]	Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. doi: 10.1001/jama.2016.0287 pmid: 26903338
[5]	Piccioni A, Santoro MC, de Cunzo T, et al. Presepsin as early marker of sepsis in emergency department: a narrative review[J]. Medicina (Kaunas), 2021, 57(8): 770.
[6]	Ward TL, Goto K, Altosaar I. Ingested soluble CD14 contributes to the functional pool of circulating sCD14 in mice[J]. Immunobiology, 2014, 219(7): 537-546. doi: 10.1016/j.imbio.2014.03.008 pmid: 24703105
[7]	Ackland GL, Prowle JR. Presepsin: solving a soluble (CD14) problem in sepsis?[J]. Intensive Care Med, 2015, 41(2): 351-353. doi: 10.1007/s00134-014-3642-8 pmid: 25608923
[8]	李丹, 陈兴明, 胡志娜, 等. Presepsin对脓毒症3.0定义下脓毒症诊断价值的meta分析[J]. 标记免疫分析与临床, 2022, 29(5): 731-735.
[9]	Lee S, Song J, Park DW, et al. Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ f ailure, sepsis, and septic shock: a prospective observational study according to the sepsis-3 definitions[J]. BMC Infect Dis, 2022, 22(1): 8. doi: 10.1186/s12879-021-07012-8
[10]	Chen M, Zhu Y. Utility of sTREM-1 and Presepsin (sCD14-ST) as diagnostic and prognostic markers of sepsis[J]. Clin Lab, 2020, 66(4). doi: 10.7754/Clin.Lab.2019.190508.
[11]	Maddaloni C, De Rose DU, Santisi A, et al. The emerging role of presepsin (P-SEP) in the diagnosis of sepsis in the critically ill infant: a literature review[J]. Int J Mol Sci, 2021, 22(22): 12154. doi: 10.3390/ijms222212154
[12]	Poggi C, Lucenteforte E, Petri D, et al. Presepsin for the diagnosis of neonatal early-onset sepsis: a systematic review and meta-analysis[J]. JAMA Pediatr, 2022, 176(8): 750-758. doi: 10.1001/jamapediatrics.2022.1647 pmid: 35639395
[13]	林巧, 王华. 血清presepsin(sCD14-ST)检测对新生儿败血症诊断价值的meta分析[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(6): 699-708.
[14]	Golovnya EG, Kharitidi TY, Sotnikov AV, et al. Diagnostic levels of sepsis biomarkers in children with oncological diseases[J]. Klin Lab Diagn, 2022, 67(1): 13-18. doi: 10.51620/0869-2084-2022-67-1
[15]	Arıkan K, Karadag-Oncel E, Aytac S, et al. Usage of plasma presepsin, C-reactive protein, procalcitonin and proadrenomedullin to predict bacteremia in febril neutropenia of pediatric hematological malignancy patients[J]. Lab Med, 2021, 52(5): 477-484. doi: 10.1093/labmed/lmab002 pmid: 33851202
[16]	Tanır Basaranoglu S, Karadag-Oncel E, Aykac K, et al. Presepsin: a new marker of catheter related blood stream infections in pediatric patients[J]. J Infect Chemother, 2018, 24(1): 25-30. doi: S1341-321X(17)30191-5 pmid: 28919353
[17]	刘新光, 李清涛, 张玉东, 等. 儿童血流感染病原菌分布情况及mNAP、Presepsin、TREM-1的早期预测价值[J]. 疑难病杂志, 2021, 20(4): 378-382.
[18]	Yoon SH, Kim EH, Kim HY, et al. Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis[J]. BMC Infect Dis, 2019, 19(1): 760. doi: 10.1186/s12879-019-4397-1 pmid: 31470804
[19]	Hu B, Tao Y, Shao Z, et al. A comparison of blood pathogen detection among droplet digital PCR, metagenomic next-generation sequencing, and blood culture in critically ill patients with suspected bloodstream infections[J]. Front Microbiol, 2021, 12: 641202. doi: 10.3389/fmicb.2021.641202
[20]	杨梅, 钱素云. 提高精准抗感染诊疗能力,改善儿童脓毒症预后[J]. 中华急诊医学杂志, 2022, 31(6): 711-713.
[21]	Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)[J]. Clin Chim Acta, 2011, 412(23-24): 2157-2161. doi: 10.1016/j.cca.2011.07.024 pmid: 21839732
[22]	Volanakis JE. Human C-reactive protein: expression, structure, and function[J]. Mol Immunol, 2001, 38(2-3): 189-197. doi: 10.1016/s0161-5890(01)00042-6 pmid: 11532280
[23]	刘霜, 惠奕, 李宁, 等. 血清Presepsin在儿童脓毒症诊断及病情评估中的应用[J]. 中国小儿急救医学, 2021, 28(12): 1082-1088.
[24]	刘晖, 赵培然, 官丽梅, 等. 脓毒症患儿血清Presepsin和炎症因子与预后的相关性分析[J]. 中华医院感染学杂志, 2020, 30(3): 438-442.
[25]	占刘英, 陈见南. 可溶性白细胞分化抗原14亚型、降钙素原及乳酸在脓毒症患儿诊断与预后评估中的价值[J]. 中国医刊, 2021, 56(3): 287-290.
[26]	Hassuna NA, Elgezawy E, Mousa SO, et al. Diagnostic value of monocyte chemoattractant Protein-1, soluble mannose receptor, Presepsin, and Procalcitonin in critically ill children admitted with suspected sepsis[J]. BMC Pediatr, 2021, 21(1): 458. doi: 10.1186/s12887-021-02930-7 pmid: 34666725
[27]	王芳, 黄声雷, 林见敏, 等. 血清降钙素原可溶性白细胞分化抗原14亚型联合血培养应用对脓毒症的诊断价值[J]. 中国药物与临床, 2022, 22(1): 29-31.
[28]	Sakyi SA, Enimil A, Adu DK, et al. Individual and combined bioscore model of presepsin, procalcitonin, and high sensitive C - reactive protein as biomarkers for early diagnosis of paediatric sepsis[J]. Heliyon, 2020, 6(9): e04841. doi: 10.1016/j.heliyon.2020.e04841
[29]	杨帆, 刘君, 王丹, 等. Presesin联合降钙素原对脓毒症患儿28d病死率预测价值研究[J]. 临床急诊杂志, 2021, 22(1): 15-20.
[30]	Xiao H, Wang G, Wang Y, et al. Potential Value of Presepsin Guidance in Shortening Antibiotic Therapy in Septic Patients: a multicenter, prospective cohort trial[J]. Shock, 2022, 57(1): 63-71. doi: 10.1097/SHK.0000000000001870
[31]	Velissaris D, Zareifopoulos N, Karamouzos V, et al. Presepsin as a diagnostic and prognostic biomarker in sepsis[J]. Cureus, 2021, 13(5): e15019.
[32]	朱孟沙, 张贵英, 赵清娟, 等. 血浆Presepsin在小儿脓毒症早期诊断及预后评估中的临床应用[J]. 中国医药, 2020, 15(7): 1102-1105.
[33]	黄文辉, 何轶群, 李娟, 等. sTREM-1、Presepsin对儿童脓毒症诊断和预后评估的价值[J]. 中国现代医学杂志, 2021, 31(19): 7-13.
[34]	Miyoshi M, Inoue Y, Nishioka M, et al. Usefulness of presepsin / creatinine ratio as a new index that corrects for renal function[J]. J Med Invest, 2021, 68(1.2): 105-111. doi: 10.2152/jmi.68.105
[35]	Kobayashi S, Amano H, Terawaki H, et al. Prediction of presepsin concentrations through commensurate decline in kidney function in the elderly[J]. Clin Chim Acta, 2020, 500: 1-9. doi: S0009-8981(19)32050-9 pmid: 31593686
[36]	Miyoshi M, Inoue Y, Nishioka M, et al. Clinical evaluation of presepsin considering renal function[J]. PLoS One, 2019, 14(9): e0215791. doi: 10.1371/journal.pone.0215791
[37]	Tanimura S, Fujieda Y, Kono M, et al. Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus[J]. Mod Rheumatol, 2018, 28(5): 865-871. doi: 10.1080/14397595.2017.1408755 pmid: 29239264
[38]	Echeverri A, Naranjo-Escobar J, Posso-Osorio I, et al. Neutrophil CD64 expression, procalcitonin and presepsin are useful to differentiate infections from flares in SLE patients with SIRS[J]. Lupus, 2018, 27(7): 1130-1139. doi: 10.1177/0961203318763740 pmid: 29540108
[39]	Ikegame A, Kondo A, Kitaguchi K, et al. Presepsin production in monocyte/macrophage-mediated phago-cytosis of neutrophil extracellular traps[J]. Sci Rep, 2022, 12(1): 5978. doi: 10.1038/s41598-022-09926-y
[40]	Takeshita S, Nakatani K, Tsujimoto H, et al. Increased levels of circulating soluble CD14 in Kawasaki disease[J]. Clin Exp Immunol, 2000, 119(2): 376-381. pmid: 10632678